Comparing visual outcome of laser in situ keratomileusis and implantable collamer lens in moderate myopia

Session Details

Session Title: LASIK Outcomes and Refinements

Session Date/Time: Monday 09/10/2017 | 14:30-15:50

Paper Time: 14:30

Venue: Room 4.4

First Author: : N.Sharma INDIA

Co Author(s): :    S. Khokhar   G. Bharanibabu   M. Mahabir              

Abstract Details

Purpose:

The studies conducted till now are favoring ICL is a good option for myopia than LASIK. But all the studies conducted on U.S and Japanese population. There is a difference in morphology of Indian eye compared to those population. This study intends to compare results in Indian population

Setting:

Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India

Methods:

Prospective comparative interventional clinical study. Inclusion criteria: Myopia (4-7D), age 21-30yrs, stable refraction for a period of 2yrs, central corneal thickness- 500 μm or more 5, predicted post-op residual stromal bed 300 μm and more, normal intraocular pressure. 6 months follow-up 6, Investigations related to project: UCVA, BSCVA by Snellen charts, Final PMT, Auto-refraction, Tear film break-up time, Schirmer's test, FACT for contrast sensitivity, USG pachymetry for corneal thickness, Slit lamp examination, noncontact tonometer for IOP measurement, Indirect ophthalmoscopy for fundus examination, I tracer for high order aberrations, specular microscopy for endothelial count.

Results:

Immediate post-operative refraction of within 1 Dioptre of refractive error achieved in 98 percent in ICL group, while in Lasik group only 85 percent achieved this dioptre. There was no difference in the pre-operative as well as postoperative higher order aberration in the ICL group, while in the Lasik group, higher order aberrations were induced. FACT and contrast ws better in ICL group compared to Lasik.

Conclusions:

Final visual acuity at 6 months was equal in the two groups with no regression, hence both the procedures can be used based on surgeon preference.

Financial Disclosure:

NONE